Allergan and Endo Pharma Under StockCall's Microscope: Drug Companies Restructure Their Businesses

Mon Feb 25, 2013 8:02am EST

* Reuters is not responsible for the content in this press release.

Allergan and Endo Pharma Under StockCall's Microscope: Drug Companies Restructure Their

LONDON, February 25, 2013 /PRNewswire/ --

    The drug manufacturing sector is always on the run. While some companies are getting
new product approvals, others are being targeted for a takeover bid. Allergan Inc. (NYSE
: AGN) is looking to perform better this year with new FDA approval for its breast
implants. Endo Health Solutions Inc. (NASDAQ : ENDP), on the other hand, is on the verge
of being acquired. Apart from this, the company's stock is also being lapped up by hedge
funds, indicating a good future for the stock. Overall, the sector looks promising.
StockCall has released full comprehensive research on Allergan and Endo Pharmaceuticals
and these free technical analyses can be downloaded by signing up at  

    Endo Health Solutions Inc. Inks Deal with GVK Biosciences  

    Endo Health Solutions Inc. is currently rumored to be the target of a takeover bid.
The company stock lost 20 percent of its value in the past 52 weeks and now its largest
shareholder wants the company to find itself a buyer. Any such sale is likely to be made
at a premium to the company's current market price and hence will bring additional value
to its shareholders. Register today and access the free research on Endo Pharmaceuticals
Holdings Inc. at  

    Endo Health Solutions Inc. recently provided conservative estimates for its pain
drug, Opana ER. The cut in estimates was mainly made due to the introduction of a
generic version of the drug. However, it seems that the company had overestimated the
negative impact of the generic drug. However, currently the bigger story about the
company is its potential to be a takeover target. It is rumored that the company may be
acquired by Valeant Pharmaceuticals or Warner Chilcott.  

    Even if there is no sale, Endo Health Solutions Inc. is firmly planning for growth
as it inked a new deal with GVK Biosciences for developing and marketing new clinical
drugs. The stock is also being picked up by Steve Cohen's SAC Capital Advisors which now
has 4.6 million shares stake in the company. Hedge Fund D.E. Shaw also has a stake in
the company.  

    Allergan Inc. May Sell Obesity Unit  

    Allergan Inc. is scaling new highs as the stock surpassed its previous 52-week high.
The company also paid 5 cents per share in dividend. It also received the FDA approval
for its new breast implants. On the growth front, the company acquired MAP
Pharmaceuticals and the company is expected to gain foothold with this new acquisition.
The company will augment its migraine portfolio with this acquisition. Allergan Inc. is
looking to restructure its business. So, along with acquisitions, it also plans to
dispose of some of its units. The company may look into selling its obesity units. Free
technical analysis on Allergan Inc. available by signing up at  

    Allergan Inc. also recently announced its fourth quarter results, and beat consensus
estimates by announcing $1.21 per share EPS. Its revenue for the quarter stood at $1.51
billion. As for fiscal 2013, the company expects its earnings to be in the range of
$4.75 and $4.83 while its full year sales are expected to remain between $5.99 billion
and $6.29 billion. The company stock is up 23 percent in the past 52 weeks and on the
back of its good outlook, it is expected to keep performing well.  

    Allergan Inc. currently draws a big chunk of its revenue from its Botox products and
it is a market leader in the segment. The company stock is expected to perform better in
the future with its new business restructuring program.  

    About is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to
talk to our financial analyst at

CONTACT:  William T. Knight, Email:, Contact Number:
+1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.